Brookline Capital Management Weighs in on Caribou Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Brookline Capital Management raised their Q3 2024 EPS estimates for shares of Caribou Biosciences in a report issued on Tuesday, August 6th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn ($0.41) per share for the quarter, up from their previous estimate of ($0.45). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.80) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.76) EPS, FY2025 earnings at ($2.92) EPS, FY2026 earnings at ($2.78) EPS and FY2028 earnings at ($0.71) EPS.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research report on Wednesday, July 17th. Evercore ISI downgraded shares of Caribou Biosciences from an “outperform” rating to an “inline” rating and cut their target price for the stock from $13.00 to $3.00 in a research report on Monday, June 3rd. Truist Financial reiterated a “buy” rating and issued a $19.00 target price on shares of Caribou Biosciences in a research report on Thursday, May 16th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Caribou Biosciences Stock Down 4.0 %

CRBU stock opened at $1.94 on Friday. Caribou Biosciences has a 12-month low of $1.50 and a 12-month high of $8.33. The company has a market cap of $175.22 million, a price-to-earnings ratio of -1.34 and a beta of 2.30. The company has a 50 day moving average of $1.98 and a two-hundred day moving average of $4.02.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. Caribou Biosciences had a negative net margin of 345.05% and a negative return on equity of 33.42%. The company had revenue of $3.46 million during the quarter, compared to the consensus estimate of $3.31 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Caribou Biosciences by 66.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock worth $88,000 after acquiring an additional 6,798 shares during the period. Entropy Technologies LP bought a new position in Caribou Biosciences in the 1st quarter worth $113,000. Raymond James Financial Services Advisors Inc. bought a new position in Caribou Biosciences in the 4th quarter worth $150,000. Bayesian Capital Management LP bought a new position in Caribou Biosciences in the 1st quarter worth $151,000. Finally, Walleye Trading LLC bought a new position in Caribou Biosciences in the 1st quarter worth $155,000. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.